For the quarter ending 2026-03-31, NWBO made $494K in revenue. -$2,904K in net income. Net profit margin of -587.85%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and other | 494 | 672 | 200 | 131 |
| Research and development | 4,858 | 5,554 | 7,450 | 7,430 |
| General and administrative | 6,536 | 8,622 | 7,070 | 7,480 |
| Total operating costs and expenses | 11,394 | 14,176 | 14,520 | 14,910 |
| Loss from operations | -10,900 | -13,504 | -14,320 | -14,779 |
| Foreign currency transaction gain (loss) | - | - | - | 3,640 |
| Settlement gain | 2,250 | - | - | - |
| Change in fair value of derivative liabilities | 9,416 | 1,177 | -3,332 | 724 |
| Change in fair value of share payable | 201 | -33 | -118 | -240 |
| Change in fair value of convertible notes | 5,235 | 19,559 | -15 | 2,392 |
| Loss from extinguishment of debt | -4,756 | -1,595 | -4,004 | -4,516 |
| Loss from issuance of debt | -738 | -1,100* | -1,611 | -773 |
| Inducement expense | 87 | - | - | - |
| Interest expense | 2,346 | 2,646 | 2,621 | 1,826 |
| Foreign currency transaction gain (loss) | -1,344 | -1,007* | -808 | - |
| Total other income (expense) | 7,831 | 14,355 | -12,509 | -599 |
| Loss before income taxes | - | 1,254* | - | - |
| Income tax benefit | - | -134* | - | - |
| Net gain | -3,069 | 1,388 | -26,829 | -15,378 |
| Deemed dividend related to warrant modifications | 331 | 137 | 353 | 560 |
| Net gain attributable to common stockholders | -3,400 | 1,251 | -27,182 | -15,938 |
| Foreign currency translation adjustment | -496 | -292 | -632 | 3,248 |
| Total comprehensive gain | -2,904 | 1,543 | -26,550 | -19,186 |
| Basic EPS | 0 | 0 | -0.02 | -0.01 |
| Diluted EPS | 0 | 0 | -0.02 | -0.01 |
| Basic Average Shares | 1,584,843,000 | 5,822,362,227 | 1,492,079 | 1,438,198 |
| Diluted Average Shares | 1,584,843,000 | 5,822,362,227 | 1,492,079 | 1,438,198 |
NORTHWEST BIOTHERAPEUTICS INC (NWBO)
NORTHWEST BIOTHERAPEUTICS INC (NWBO)